At CAGR of 3.3% Global Etanercept Market Size & Share | 2022 – 2028 | Projected to Hit at USD 20.8 Billion: Etanercept Industry Trends, Value, Analysis & Forecast Report by Facts & Factors – Press Release

NEW YORK, United States, May 10, 2022 (GLOBE NEWSWIRE) — Facts and Factors has published a new research report titled “Etanercept Market By Application (Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Others), By Distribution Network (Online and Offline), and By Region-Global and Regional Industry Trends, Competitive Intelligence, Analysis of Data, Statistical Data, and Forecast 2022-2028” in its research database.

“According to the latest research study, the demand of global Etanercept Market size & share was witnessed about USD 15.5 billion in 2021and it is expected to surpass around USD 20.8 billion Mark, by 2028, at a compound annual growth rate (CAGR) of about 3.3% during the forecast period 2022 to 2028.”

What is Etanercept? How big is the Etanercept Industry?

Report Overview:

Etanercept is a biopharmaceutical anti-Tumor Necrosis Factor (TNF) agent used to treat autoimmune diseases like spondylitis and arthritis. TNF overproduction in the body causes pain, inflammation, and bone & joint damage.

Etanercept inhibits TNF action and thus reduces inflammation. It’s used to treat rheumatoid arthritis, juvenile rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Get a Free Sample PDF of this Research Report for more Insights with a Table of Content, Research Methodology, and Graphs – https://www.fnfresearch.com/sample/etanercept-market

(A free sample of this report is available upon request; please contact us for more information.)

Our Free Sample Report Consists of the Following:

• Introduction, Overview, and in-depth industry analysis are all included in the 2022 updated report.
• The COVID-19 Pandemic Outbreak Impact Analysis is included in the package
• About 221+ Pages Research Report (Including Recent Research)
• Provide detailed chapter-by-chapter guidance on Request
• Updated Regional Analysis with Graphical Representation of Size, Share, and Trends for the Year 2022
• Includes Tables and figures have been updated
• The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis
• Facts and Factors research methodology

(Please note that the sample of this report has been modified to include the COVID-19 impact study prior to delivery.)

Report Scope

Global Etanercept Market: Dynamics

During the forecast period, the global etanercept market is expected to grow at a rapid pace. This is due to an increase in the prevalence of lifestyle disorders, obesity, accidents, and spondylitis. When compared to certain other therapeutic proteins, Enbrel has seen a significant increase in demand. It is used to treat auto-immune diseases like psoriasis, juvenile rheumatoid arthritis, and plaque. The higher incidence of these diseases is estimated to propel the etanercept market.

Furthermore, technological advancements and R & D activities may introduce new opportunities in the global market. However, rising overall treatment costs, the absence of reimbursement policies in developing nations, and treatment side effects are expected to restrain the global market.

Browse the full “Etanercept Market By Application (Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Others), By Distribution Network (Online and Offline), and By Region-Global and Regional Industry Trends, Competitive Intelligence, Analysis of Data, Statistical Data, and Forecast 2022-2028” Report at https://www.fnfresearch.com/etanercept-market

Etanercept Market: COVID-19 Impact Analysis

Every industry in the world has suffered a setback in the last 18 months, with the exception of those in the undeveloped nations. Due to several precautionary lockdowns and other limitations imposed by governing bodies around the world, considerable disruptions in their respective industrial and supply-chain operations have occurred. Etanercept is a drug that has been approved for use in humans.

Moreover, consumer demand has subsequently fallen as consumers have been more concerned with cutting non-essential costs from their corresponding expenditures as the overall economic situation of the majority of the population has been badly damaged by this outbreak. Over the projected period, it is anticipated that these variables would have an impact on the global market’s revenue growth. Global markets, on the other hand, are anticipated to rebound as the individual governments begin to ease the restrictions that have been placed.

Etanercept Market: Segmentation Analysis

The global etanercept market is segregated on the basis of application, distribution network, and region.

By application, the market is divided into juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and others. In the year 2021, rheumatoid arthritis held a commanding market share. It is due to the high prevalence of osteoarthritis in different regions around the world.

By distribution network, the market is divided into online and offline. In 2021, the offline segment held a commanding market share. It is due to reimbursement policies and the increasing adoption of AI as a supplement to a simple purchase.

Directly Purchase a copy of the report with TOC @ https://www.fnfresearch.com/buynow/su/etanercept-market

Competitive Landscape

Some of the main competitors dominating the global etanercept market include – 

• GlaxoSmithKline
• Novartis
• Takeda
• Clover Biopharmaceuticals
• Johnson & Johnson
• Roche
• Celltrion
• Pfizer
• Cipla
• Samsung Bioepis

Key Insights from Primary Research:

• As per the analysis shared by our research analyst, the Etanercept market is estimated to grow at a CAGR of around 3.3% during the forecast period.
• The Etanercept market was valued at around US$ 15.5 billion in 2021 and is projected to reach US$ 20.8 billion by 2028.
• Based on application segment, the rheumatoid arthritis dominated the market. It is owing to the increased frequency of osteoarthritis globally.
• By distribution network, the offline segment dominated the market. It’s because of reimbursement restrictions and the rising use of AI to complement purchases.
• On the basis of region, the North America’s etanercept market held a 33% share when compared to other areas. Due to the presence of major pharma conglomerates. However, between 2022 and 2028, Asia Pacific is expected to be a profitable venture for marketers.

Key questions answered in this report:

• What is the market size and growth rate forecast for Etanercept industry?
• What are the main driving factors propelling the Etanercept Market forward?
• What are the leading companies in the Etanercept Industry?
• What segments does the Etanercept Market cover?
• How can I receive a free copy of the Etanercept Market sample report and company profiles?

Have Any Query? Ask Our Experts: https://www.fnfresearch.com/inquiry/etanercept-market

Regional Dominance:

North America’s market is expected to expand rapidly in the coming years. The region’s dominance in the global etanercept market is due to favorable reimbursement scenarios, acceptance of advanced techniques, and a technically sophisticated health care system. Etanercept’s other major markets are Europe and the Asia Pacific.

The presence of key players, increased investments in R&D activities by major pharma players, and collaborative partnerships between pharma & biotech companies and research institutes drive the etanercept market in these regions.

Recent Developments

Recent Development

• December 2019: Clover Biopharma has begun Phase III studies in China for the Etanercept Biosimilar Candidate SCB-808. The first patient was given an injection of the biosimilar being developed in the preloaded syringe composition for the treatment of rheumatic diseases such as ankylosing spondylitis and rheumatoid arthritis, according to the company. The purpose of this study is to compare the efficacy, safety, and pharmacokinetics of SCB-808 and the originator drug Enbrel® in patients with ankylosing spondylitis after subcutaneous administration. 
• November 2019: Samsung Bioepis and Biogen have announced a major commercialization agreement for two biosimilar applicants. The agreement gives Biogen the option to renew the commercialization term for Samsung Bioepis’ three anti-TNF biosimilars – BENEPALI (etanercept), IMRALDI (adalimumab), and FLIXAB (infliximab) – in Europe for an additional five years, bringing the original ten-year agreement to a total of fifteen years. In Germany, France, Spain, Italy, and the United Kingdom, BENEPALI is the most commonly prescribed etanercept (UK). In Europe, IMRALDI is the leading adalimumab biosimilar. The agreement also gives Biogen the option of getting commercialization rights to BENEPALITM, FLIXABITM, and IMRALDITM in China in exchange for market royalties.

Request for Customization on this Report as per your requirements – https://www.fnfresearch.com/customization/etanercept-market

(We tailor your report to meet your specific research requirements. Inquire with our sales team about customising your report.)

The global etanercept market is segmented as follows:

By Application

• Juvenile Idiopathic Arthritis
• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Others

By Distribution Network

By Region

• North America
  • U.S.
  • Canada
  • Rest of North America
• Europe
  • France
  • UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

Request For Free Sample Report of the Global Etanercept Market @ https://www.fnfresearch.com/sample/etanercept-market

Browse Other Related Research Reports from Facts & Factors:

In Vitro Fertilization (IVF) Market By Type (Conventional IVF, IVF with ICSI, IVF with Donar Eggs, Others), By Cycle (Fresh Non-donor IVF Cycles, Frozen Non-donor IVF Cycles, Frozen Donor IVF Cycles, Fresh Donor IVF Cycle), By Product (Equipment, Sperm Analyzer Systems, Imaging Systems, Ovum Aspiration Pumps, Micromanipulator Systems, Incubators, Gas Analyzers, Laser Systems, Cryosystems, Sperm Separation Devices, IVF Cabinets, Anti-vibration Tables, Witness Systems, Other Equipment, Reagents & Media, Cryopreservation Media, Embryo Culture Media, Ovum Processing Media, Sperm Processing Media, Accessories), By End User (Fertility Clinics, Hospitals & Surgical Centers, Cryobanks, Research Institutes), and By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecast 2022–2028

Blood Pressure Monitoring Devices Market By Product (Ambulatory Blood Pressure Monitor, Digital Blood Pressure Monitor, Sphygmomanometer, Transducers, and Instruments & Accessories), By End-User (Home Healthcare, Hospitals, Ambulatory Surgical Centers & Clinics), and By Region-Global and Regional Market Dynamics, Data Analytics, Consumer Demand, Statistical Surveys, Extensive Research, Historical Trends, Current Patterns, and Forecast 2022–2028

Non-Insulin Therapies for Diabetes Market By Product Type (Oral & Injectable) and By Distributor (Retail Pharmacies, Hospital Pharmacy, Online Pharmacy, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast 2021 – 2028

E-Clinical Solutions Market By Product (Electronic Data capture (EDC) and Clinical Data Management Systems (CDMS), Clinical Trial Management Systems (CTMS), Clinical Analytics Platform and Trial Supply Management (RTMS), Clinical Data Integration Platform, Safety Solutions, Electronic Clinical Outcome Assessment (eCOA), Electronic Trail Master Files (eTMF), and Others), By Delivery Mode (Web-Hosted Services, On-Premises Solutions, & Cloud-based Services), By Clinical Phase Trials (Phase I, Phase II, Phase III, & Phase IV), By Industry Verticals (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations, Consulting Service Companies & Academic Research Institutions, Medical Device Manufacturers, and Hospitals & clinics, and Others), and By Regions – Global Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2026

Dental Periodontics Market By Product (Injectable Anesthetics, Gelatin-Based Hemostats, Topical Anesthetics, Dental Hemostats, Dental Anesthetics, Oxidized Regenerated Cellulose-Based Hemostats, Collagen-Based Hemostats, Dental Sutures, Non-Absorbable Dental Sutures, Absorbable Dental Sutures, X-Ray, Intraoral Cameras, Optical Imaging, Cone Beam Computed Tomography (CBCT), Infection Control, Sanitizing Gels, Disinfectants, and Personal Protective Wear), By Type (Mild Periodontics and Advanced Periodontics), By Application (Dental Laboratories, Dental Hospital, Dental Clinics, and Others), And By Regions – Global & Regional Industry Perspective, Comprehensive Analysis, and Forecast 2021 – 2026

Dental Insurance Market By Insurance Type (Basic/Minor, Major & Preventive), By Mode of Distribution (Corporates, Insurance Agents and Online Channel), and By End-User (Families and Individuals): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2021-2027

About Facts & Factors:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds.

Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Follow Us on LinkedIn: https://www.linkedin.com/company/fnfresearch

Follow Us on Twitter: https://twitter.com/fnfresearch

Follow Us on Facebook: https://www.facebook.com/factsandfactors/

Contact Us:

Sanu Thomas

USA: +1 347 690-0211

United Kingdom: +44 2032 894158

Japan: +81 50 5806 9039

India: +91 96043 17127

Email: sales@fnfresearch.com

Web: https://www.fnfresearch.com

Blog: https://www.fnfresearch.com/blog/